In this context, the phase 2 ORACLE-RIPA clinical study, focusing on the time-dependent immune modulation effects of CDK4/6 inhibitors in ER-positive/HER2-negative early breast cancer patients, would help toward the identification of immune-related signatures associated with better response to these drugs (NCT05766410). The gene discussed is CDK4; the disease is breast carcinoma.